 UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical-stage biotechnology company focused on developing bispecific gamma delta T cell engagers bsTCEs to transform the treatment of cancer, today announced that Hans van der Vliet, M.D,. Ph.D., chief scientific officer at LAVA, will present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021. 